Please select the option that best describes you:
Are there instances where you would offer erdafitinib instead of avelumab for maintenance therapy for FGFR3 mutated metastatic bladder cancer after stable disease on cisplatin/gemcitabine?
Is there concern for increased toxicity from erdafitinib following avelumab similar to osimertinib toxicity following pembrolizumab in NSCLC? Does FGFR3 mutation predict for lack of immunotherapy response?
Answer from: Medical Oncologist at Community Practice
The short answer is 'no'. There are no data for supporting FGFR inhibition in a maintenance first-line setting for those with stable or responding disease on platinum-based chemotherapy and FGFR2/3 activating alterations. There are contrasting data suggesting that the activity of PD1/L1 inhibitors m...
Sign in or Register to read more